investigational pd-l1–targeted immunotherapy safe for patients with triple-negative breast cancer
Published 9 years ago • 524 plays • Length 20:43Download video MP4
Download video MP3
Similar videos
-
5:25
investigational pd-l1–targeted immunotherapy safe for patients with triple-negative breast cancer
-
1:33
comment: metastatic triple-negative breast cancer responds to immunotherapy
-
6:10
pd-1 inhibitor pembrolizumab shows promising clinical activity for triple-negative breast cancer
-
3:26
pd-1 therapy with eribulin for triple negative mbc
-
2:10
testing and targeted therapy in triple negative breast cancer: 2023 west oncology
-
3:37
case 3: pd-l1 testing used in triple-negative breast cancer
-
0:53
keynote-522 demonstrates potential for immunotherapy in triple-negative breast cancer
-
15:25
targeted therapies: the future of non-small cell lung cancer (nsclc) treatment?
-
45:09
breast cancer: the latest target for immunotherapy, with leisha emens
-
0:58
immune checkpoint inhibitors: recent progress and potential biomarkers - 3iii pd-l1 overexpression
-
1:30
emerging immunotherapy beyond checkpoint inhibitors for tnbc
-
1:03
new directions in immunotherapy for improving outcomes in tnbc
-
0:46
immune checkpoint inhibitors: recent progress and potential biomarkers - 3iv pd-l1 overexpression
-
0:41
recent advances in targeted therapies for tnbc
-
1:38
combined analyses of pd-l1 and tils for therapy selection in tnbc
-
1:17
neoadjuvant immunotherapy in tnbc and targeted lnd in breast cancer: 2023 best of breast conference
-
57:18
translating progress with immunotherapies and targeted agents into improved outcomes in tnbc
-
1:28
recent developments in treating tnbc with targeted therapies
-
1:36
dr. hurvitz on pembrolizumab for tnbc